Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Ariosa Dx Q1 Revenues Double, Posts Profit

The story has been updated to clarify Ariosa's earnings per share for the first quarter of 2014.

NEW YORK (GenomeWeb News) – Ariosa Diagnostics' first quarter revenues more than doubled year over year, the company said in an amended Form S-1 on Wednesday.

For the three months ended March 31, revenues shot up to $19.5 million from $9.6 million in the first quarter of 2013 as revenues from its partnership with Laboratory Corporation of America, as well as from international customers, increased, the San Jose, Calif.-based developer of non-invasive prenatal tests said.

Ariosa and LabCorp partnered in 2012 to make Ariosa's Harmony Prenatal Test available in the US and Canada. In the recently completed quarter, LabCorp-related revenues accounted for 62 percent of total revenues, down from 94 percent in the year-ago first quarter. During 2013 Ariosa entered into agreements with an additional unnamed US healthcare provider and with international clinics to offer Harmony, contributing to the year-over-year bump-up in revenues, it said.

Revenues from its international business grew to $6.9 million in Q1 2014 from $583,000 in the year-ago period as test volume grew.

Ariosa posted a profit of $1.1 million for the quarter. The firm did not provide a per-share earnings figure. In an e-mail to GenomeWeb Daily News, a spokesman said that while the company made money, the net income was payable to preferred shareholders "given that they were entitled to an 8 percent dividend."

During the first quarter of 2013, Ariosa had a net loss of $2.5 million, or $1.47 per share.

Its R&D expenses rose 19 percent to $4.3 million from $3.6 million, while its SG&A costs were up 61 percent to $8.2 million from $5.1 million.

Ariosa finished the first quarter with $16.8 million in cash and cash equivalents.

The company filed a preliminary prospectus with the US Securities and Exchange Commission last month for an initial public offering. Ariosa has not yet priced the IPO.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.